Research Papers:
Serum XPNPEP2 levels correlate with lymph node metastasis in Pca patients
Fei Li1,*, Mengqin Lv1,*, Hao Xu2, Kecheng Huang1, Ying Zhou1, Rong Liu3, Danfeng Luo1, Ding Ma1, Ling Xi1 and Xiangyi Ma1
1Cancer Biology Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
2Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
3Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
*These authors have contributed equally to this article as the first author
Correspondence to:
Xiangyi Ma, email: [email protected]
Keywords: biomarker; XPNPEP2; prostate cancer; lymph node metastasis
Received: May 17, 2017 Accepted: February 28, 2018 Published:
ABSTRACT
The biological and clinical significance of Aminopeptidase P2 in human cancers remains unknown. In this study, we demonstrated that XPNPEP2 was highly expressed in the prostate. Additionally, we used TCGA, IHC and ELISA to analyze the expression of XPNPEP2 in tissues and serum from prostate cancer patients. XPNPEP2 expression was lower in prostate cancer tissue than in normal prostate tissue but was higher in Prostate cancer tissue with local invasion and LN metastasis than in tissue with localized Pca. Serum XPNPEP2 levels were different in Pca patients with and without lymph node metastasis. We demonstrated Serum XPNPEP2 levels correlate with lymph node metastasis in Pca patients. An ROC analysis revealed that a combination of PSA and XPNPEP2 was more efficient than PSA or XPNPEP2 alone for predicting LN metastasis, especially for Pca patients with low serum PSA levels.